Breeze Holdings Acquisition Corp. to merge with YD Biopharma Limited to revolutionize cancer prevention diagnostics
Acquiring Company
Breeze Holdings Acquisition
Acquired Company
YD Bio Limited
Assam
IrvingBiotechnologyFinancial ServicesHealth CareArtificial IntelligenceFinanceVenture CapitalBiotechnologyHealth CareMedicalTherapeuticsBiopharmaDescription
Breeze Holdings Acquisition Corp. (BRZH, BRZHR, BRZHW) has entered into a definitive agreement to merge with YD Biopharma Limited, a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases. Upon the closing of the merger, the combined company is expected to be listed on the Nasdaq Capital Market. The merger will enable Breeze to leverage YD Biopharma's advancements in biotechnology and expand its presence in the clinical trials and cancer prevention diagnostics market.
Quick answer
Breeze Holdings Acquisition is acquiring YD Bio Limited, announced September 25, 2024. Breeze Holdings Acquisition is based in Assam, India.
- How much did Breeze Holdings Acquisition pay for YD Bio Limited?
- The deal value was not disclosed.
- What does Breeze Holdings Acquisition do?
- Breeze Holdings Acquisition Corp. is a special purpose acquisition company (SPAC).
- Where are Breeze Holdings Acquisition and YD Bio Limited based?
- Breeze Holdings Acquisition is based in Assam, India. YD Bio Limited is based in Irving, Texas, United States.
Source: Fundz verified event record.
Other recent acquisitions in Financial Services and Finance
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Organon successfully acquires Dermavant Sciences Ltd. to expand dermatology portfolio (October 28, 2024)
- RadNet's DeepHealth subsidiary acquires Kheiron Medical Technologies for AI-powered diagnostic solutions (October 25, 2024)
- Flat Medical strengthens market leadership with acquisition of InjeQ assets, including FDA-Designated Breakthrough Device IQ-Tip® (September 25, 2024)
- Organon acquires Dermavant Sciences to obtain the groundbreaking skin treatment VTAMA® (tapinarof) cream 1% (September 19, 2024)
- Organon to Acquire Dermavant Sciences Ltd. with Focus on Innovative Dermatologic Therapy VTAMA® (tapinarof) Cream, 1% (September 18, 2024)
- Becton, Dickinson and Company (BDX) completes acquisition of Critical Care from Edwards Lifesciences (September 3, 2024)
Who to call at Breeze Holdings Acquisition, and when
When Breeze Holdings Acquisition changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Breeze Holdings Acquisition raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Breeze Holdings Acquisition, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Breeze Holdings Acquisition. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Breeze Holdings Acquisition makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired YD Bio Limited?
YD Bio Limited was acquired by Breeze Holdings Acquisition, based in Assam. The deal was reported on September 26, 2024. Breeze Holdings Acquisition Corp. is a special purpose acquisition company (SPAC). It is focused on merging with or acquiring one or more businesses. Breeze Holdings Acquisition is publicly traded (BREZ) and operates in Biotechnology.
When did Breeze Holdings Acquisition acquire YD Bio Limited?
Breeze Holdings Acquisition's acquisition of YD Bio Limited was reported on September 26, 2024. Breeze Holdings Acquisition Corp. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does YD Bio Limited do?
YD Bio Limited is a biotechnology company focused on advancing DNA methylation-based cancer detection technology and ophthalmologic innovations. It is publicly traded (YDES), operating in Biotechnology, and is based in Irving.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.